NCT00659282 (IMPROVE™) is a clinical trial of biphasic insulin aspart in Diabetes, sponsored by Novo Nordisk A/S.

Who is sponsoring NCT00659282?

NCT00659282 is sponsored by Novo Nordisk A/S.

What drugs are being tested in NCT00659282?

Interventions in NCT00659282: biphasic insulin aspart.

What condition does NCT00659282 study?

NCT00659282 studies Diabetes, Diabetes Mellitus, Type 2.

Is NCT00659282 still recruiting?

NCT00659282 is currently completed. Last updated 12 January 2018.

Last reviewed 2018-01-12 · How we verify

NCT00659282: IMPROVE™

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Observational Study of Safety and Effectiveness of NovoMix® 30 for the Treatment of Diabetes

Completed Last updated 12 January 2018

What this trial tests

trial testing biphasic insulin aspart in Diabetes in 57,610 participants. Completed in 15 November 2008.

Timeline

11 September 2006

Primary endpoint
15 November 2008

15 November 2008

Quick facts

Lead sponsor	Novo Nordisk A/S
Status	Completed
Study type	OBSERVATIONAL
Enrollment	57,610
Start date	11 September 2006
Primary completion	15 November 2008
Estimated completion	15 November 2008
Sites	11 locations across Italy, Japan, Russia, Greece, Saudi Arabia, Poland, South Korea, Canada

Drugs / interventions tested

biphasic insulin aspart — full drug profile →

Conditions studied

Diabetes — all drugs for Diabetes →
Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

Novo Nordisk A/S — full company profile →

Who can join

Eligibility, any sex, with Diabetes or Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is conducted in Asia, Europe, Japan and North America. The aim of this observational study is to evaluate the safety and effectiveness while using NovoMix® 30 during 26 weeks under normal clinical practice, in the countries participating in the study. The primary outcome is the incidence of major hypoglycaemic events reported as serious adverse drugs reaction conditions on hypoglycaemic events.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE observational study.
Shah S, Benroubi M, Borzi V, Gumprecht J, et al · · 2009 · cited 32× · PMID 19210701 · DOI 10.1111/j.1742-1241.2009.02012.x
Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study.
Gumprecht J, Benroubi M, Borzi V, Kawamori R, et al · · 2009 · cited 29× · PMID 19504715 · DOI 10.1111/j.1742-1241.2009.02064.x
National Variations in Comorbidities, Glycosylated Hemoglobin Reduction, and Insulin Dosage in Asian Patients with Type 2 Diabetes: The FINE-Asia Registry.
Ji L, Tsai ST, Lin J, Bhambani S. · · 2015 · cited 18× · PMID 26494149 · DOI 10.1007/s13300-015-0137-8
Predictors of achieving HbA(1c) <7% and no hypoglycaemia 6 months after initiation of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study.
Valensi P, Shaban J, Benroubi M, Kawamori R, et al · · 2013 · cited 8× · PMID 23488447 · DOI 10.1185/03007995.2013.786692
Biphasic insulin aspart 30 as insulin initiation or replacement therapy: the China cohort of the IMPROVE study.
Yang W, Gao Y, Liu G, Chen L, et al · · 2010 · cited 5× · PMID 19916705 · DOI 10.1185/03007990903364640

Verify or expand the search:

Other trials of biphasic insulin aspart

Trials testing the same drug.

NCT02762578 — Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes · Phase 3 · completed
NCT02648217 — Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in · Phase 3 · completed
NCT00184626 — Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With · Phase 4 · completed
NCT00564668 — Comparison of Biphasic Insulin Aspart Produced by the NN2000 Process to Current Process to in Type 2 Diabetes · Phase 3 · completed
NCT00592969 — Efficacy and Safety of Metformin Plus Biphasic Insulin Aspart 30 in Type 2 Diabetes · Phase 4 · completed

Other recruiting trials for Diabetes

Currently open trials in the same condition.

NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
NCT07417865 — ECHO Diabetes FQHC · recruiting

Other Novo Nordisk A/S trials

Trials by the same sponsor.

NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · not yet recruiting
NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles · Phase 3 · not yet recruiting
NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight · Phase 3 · not yet recruiting
NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe · Phase 3 · not yet recruiting
NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00659282 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
Last refreshed: 12 January 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00659282.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing